Jean-Baptiste Marchand et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – BioInvent International A.B, Sweden
Catégorie : TG6002
Premier patient traité avec le virus oncolytique TG6002 de Transgene dans un essai de Phase 1/2 chez des patients atteints de tumeurs gastro-intestinales au stade avancé
20181017 CP TG6002 FR
Transgene finalise la vente des droits de TG6002 et TG1050 pour la Grande Chine à Tasly Biopharmaceuticals en contrepartie de 48 millions de dollars en actions nouvelles de Tasly Biopharmaceuticals
180710 – TG Tasly closing CP
Transgene et Tasly Biopharmaceuticals signent des accords sur les droits en Chine de TG6002 et TG1050
180710 – TG Tasly agreement CP
TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
Johann Foloppe, et al. International Oncolytic Virus Conference, April 2018 Download the poster here Poster Presentation
Premier patient traité dans l’essai de Phase 1/2a de TG6002, virus oncolytique innovant de Transgene, dans le glioblastome récurrent
20171026 CP TG6002
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article Publication
TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
Ahmed Idbaih, et al. ASCO 2017, June 2017 – Download the abstract Abstract
Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
Johann Foloppe, et al.XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016Download the poster herePoster Presentation